An observational study in Hypertension and Heart Disease, sponsored by The University of Hong Kong-Shenzhen Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by The University of Hong Kong-Shenzhen Hospital · Observational
Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.
The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.
6,689 studies on the registry are indexed under Hypertension; 964 are open to participants now.
This study's planned enrollment of 46 is below the median of 210 across 1,358 observational studies indexed under Hypertension.
Browse Hypertension studies →The University of Hong Kong-Shenzhen Hospital is the lead sponsor of 16 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
45 patients with hypertensive heart disease admitted to Hong-Kong University, Shenzhen Hospital from January 1 to March 10 in 2021 were included in our study. Hypertensive heart disease was defined using the International Classification of Diseases, Ninth and Tenth Revision (ICD-10) codes. Diseases coded as I11.0 and I11.9 in ICD-10 were identified as hypertensive heart disease[1-2].
Exclusion Criteria:
Measurement of serum miR-455-5p level
concentration of microRNA-455-5p in 100ml serum was determined by Elisa assay.
Time frame: the miR-455-5p level is collected at week 0, 6, 12 and 24.
Measurement of LVPWd and LVPWs
left ventricular posterior wall thickness in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
Time frame: the LVPWd and LVPWs are collected at week 0, 6, 12 and 24.
Measurement of LVIDd and LVIDs
left ventricular internal diameter in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
Time frame: the LVIDd and LVIDs are collected at week 0, 6, 12 and 24.
Measurement of IVSTd and IVSTs
interventricular septum in diastole state and systole state are measured and recorded by echocardiography and its affiliated software.
Time frame: the IVSTd and IVSTs are collected at week 0, 6, 12 and 24.
Calculation of LVMi
left ventricular mass index was calculated based on the formula: LVMi=LVM/BSA; For LVM, LVM(g)=0.8\*1.04\*\[(IVSTd+LVPWd+LVIDd)\^3-LVIDd\^3\]+0.6; For BSA, BSA=\[Body height (cm)\*Body weight (kg)/3600\]\^0.5； Diagnosis of LVH: LVMi(Male)\>115g/m2；LVMi(Female)\>95g/m2
Time frame: the LVMi is calculated at week 0, 6, 12 and 24.
Measurement of LVEF
left ventricular ejection fraction are measured and recorded by echocardiography and its affiliated software. Generally, LVEF is range from 50% to 70% is regarded as normal. If LVEF less than 50%, the patient is suspected to suffered cardiac systolic dysfunction.
Time frame: the EF is calculated at week 0, 6, 12 and 24.
Measurement of FS
Fractional shortening are measured and recorded by echocardiography and its affiliated software. Generally, FS is range from 25% to 45% is regarded as normal. If FS less than 25%, the patient is suspected to suffered cardiac systolic dysfunction.
Time frame: the FS is calculated at week 0, 6, 12 and 24.
SBP
systolic blood pressure was measured by sphygmomanometer. For patients whose SBP is higher than 140mmHg, the patients is regarded as hypertension.
Time frame: the SBP is collected at week 0, 6, 12 and 24.
DBP
diastolic blood pressure was measured by sphygmomanometer. For patients whose DBP is higher than 90mmHg, the patients is regarded as hypertension.
Time frame: the DBP is collected at week 0, 6, 12 and 24.
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Hong Kong-Shenzhen Hospital